NHS Framework Agreement for the Supply of Recombinant Von Willebrand Factor
The value below is a framework or dynamic market ceiling: the maximum
that could be spent across all call-offs, not the value of a single contract.
Aggregate figures on this site exclude these to avoid double counting.
key details
| Value | £600,000 |
|---|---|
| Status | cancelled |
| Category (CPV) | 33600000 |
| Contract start | 1 Jul 2022 |
| Contract end | 30 Jun 2023 |
| Procedure | open |
| SME suitable | Yes |
| OCID | ocds-b5fd17-34b2f81b-0f3f-47db-abc4-dd6cb4a58636 |
description
Recombinant Von Willebrand Factor
Period of framework agreement: 1 July 2022 to 30 June 2023 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 36 months. Total maximum framework agreement including extension options will be no more than 48 months
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 21 Oct 2021 | Planning (planning) | · | f835a451-3d72-4617-b0ff-7e25e5146090-478907 |
more from NHS ENGLAND
- Products for the treatment of Haemophilia A · £215,000,000 · 11 May 2023
- NHS Framework Agreement for the supply of products for the treatment of Haemophilia A · £215,000,000 · 26 Apr 2023
- NHS Framework Agreement for the Supply of Human Normal Immunoglobulin & Anti-D Immunoglobulin · £526,598,540 · 3 Feb 2023
- NHS Framework Agreement for the supply of Adult Influenza Vaccines - Secondary Care · £16,000,000 · 22 Jul 2022
- National Framework Agreement for the supply of products for the management of Hereditary Angioedema · £74,500,000 · 5 Jul 2022
- NHS National Framework Agreement for the supply of products for the management of Hereditary Angioedema · £74,500,000 · 5 Jul 2022
- NHA National Framework Agreement for the supply of products for the treatment of Bleeding Disorders including Haemophilia B · £250,000,000 · 5 Jul 2022
- NHS National Framework Agreement for the supply of products for the treatment of Haemophilia A · £214,000,000 · 22 Mar 2022
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Contracts Finder. Contact details for named individuals are not reproduced on this site.